Navigation Links
The Neuropathy Association's Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
Date:11/10/2008

NEW YORK, Nov. 10 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--a national patient-based non-profit organization dedicated to finding a cure for neuropathy--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Gary J. Bennett, Ph.D. of McGill University (Quebec, Canada) and Helene Bour-Jordan, Ph.D. and co-principal investigator, Mark S. Anderson, M.D., Ph.D. of the University of California, San Francisco (UCSF) Diabetes Center--were chosen from eleven applicants involved in neuropathy research at medical institutions across North America.

Dr. Bennett's proposal, Mechanism of Paclitaxel-Evoked Peripheral Neuropathy, is based on data suggesting that paclitaxel (Taxol(R)) causes neuropathy by a novel and previously unrecognized mechanism. Paclitaxel is used by tens of thousands of patients as a first-line drug in the treatment of ovarian, breast and non-small cell lung cancer. The neuropathy, a serious side-effect of paclitaxel, can be severe---and often painful---thus preventing or limiting the use of the drug as an effective chemotherapeutic and leading to a decline in the patient's quality of life.

Dr. Bennett adds, "Preventing and controlling the neuropathy resulting from paclitaxel will, in turn, allow us to administer larger doses to more effectively kill cancer cells and save lives."

With their proposal, Identification of Neural Autoantigens in Autoimmune Peripheral Neuropathy, Drs. Bour-Jordan and Anderson hope to identify proteins of the peripheral nervous system that are targeted by the immune system in autoimmune neuropathy.

Dr. Bour-Jordan explains, "Autoantibodies in tissue-specific autoimmune diseases are excellent indicators of disease and are instrumental in identifying major autoantigens that are now used in clinical trials for several autoimmune disorders, including type 1 diabetes, multiple sclerosis and rheumatoid arthritis."

Ronnie Chalif, the Association's president affirms, "Finding a cure for neuropathy requires that we continue building upon our strategic research initiatives by making targeted investments in neuropathy research."

About Peripheral Neuropathy

Peripheral neuropathy is one of the most common diseases affecting approximately 20 million Americans.

Neuropathy results from injury to the peripheral nerves---the motor, sensory and autonomic nerves connecting the spinal cord to the muscles, skin, blood vessels and internal organs. It usually affects the hands and feet, causing weakness, numbness, lack of coordination or pain.

Approximately 30% of neuropathies are "idiopathic," meaning of an unknown cause; 30% are caused by diabetes. Other causes include autoimmune disorders, tumors, heredity, nutritional deficiencies, infections, trauma, and drugs or toxins.

About The Neuropathy Association

The Neuropathy Association(R), the leading national patient-based nonprofit organization, was established in 1995 by people with neuropathy and their families and friends to help those who suffer from disorders of the peripheral nerves. Now a national organization with over 50,000 members and supporters, 12 Association-designated neuropathy centers and 130 support groups, the Association's mission is to provide patient support and education, advocate for patients' interests, and find a cure for neuropathy.

For more information about peripheral neuropathy and The Neuropathy Association, visit http://www.neuropathy.org.


'/>"/>
SOURCE The Neuropathy Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
7. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
8. Pharmacist Associations Partner to Increase the Voice of Pharmacy
9. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY ... announced that Mercy Medical Center will serve as the official title sponsor of the ... Sunday, June 25, 2017, thousands of women will walk or run the course around ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special ... $29.97; for the remaining days of March, the price will be only $19.97. The ... price of just $10 (regular retail price $19.97). , The special promotional prices are ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wall Centre Dental team is ... from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain veneers, ... esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton Reskovich ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
(Date:3/29/2017)... ... 2017 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices has recently updated its Visio Stencils library with new ... download shapes and stencils from http://www.VisioStencils.com. , New devices were added ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology: